DSM Biomedical has obtained an exclusive worldwide license to a drug and biologics delivery system developed by MediVas LLC. The technology is based on a next-generation set of polymers exclusively licensed from Cornell University and is the result of research from both Cornell and MediVas.
The polymers are biodegradable, biocompatible and bioabsorbable as well as non-inflammatory, allowing greater control over the rate and duration of release of therapeutics. The technology can be used with a variety of drug candidates, from small molecule drugs to large molecules like proteins, peptides and nucleic acids, expanding the possible application areas of DSM's Trancerta platform. DSM's license applies to the development of drug delivery systems aimed at treating ophthalmic, CV, musculoskeletal diseases and pain relief.
"Through this deal we bring in the first fully developed biodegradable polymer into DSM's Biomedical portfolio, which significantly enhances our materials competences. This will help us realize our ambition to build a portfolio of drug delivery technologies tailored at the specific needs of the health industry. MediVas' technology is already proven in two clinical studies which should allow us to accelerate the commercialization of our drug delivery technologies in partnerships with Pharma, Biotech and Medical Device companies," said Steve Hartig, president of DSM Biomedical.